US1101221083
© BusinessWire
06.05.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company.
This press release features multimedia. View the full re...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.
“Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “We are advancing our multi-...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment dem...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
18.04.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
14.04.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) did not meet its dual primary endpoints of changes from baseline to Week 48 compared to...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common primary liver cancer.1,2 This approval is based on the results from the...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorecta...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
News Preview
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1 Expression ≥1%
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use), a new pharmaceutical form (solution for injection) and a new stren...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic thera...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investor...
Themefolio
Profiler
Peergroup
© BusinessWire
08.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). The POETYK PsA-2 trial met its primary endpoint, with a significantly greater proportion of Sotyktu-treated patients a...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
07.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
“The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence d...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025.
In addition, the Board of Directors ha...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025.
The company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 2:30 p.m. ET. In addition, the company will take part in a fireside chat at the Leerink Part...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
News Preview
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administr...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo® (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC)....
Themefolio
Profiler
Peergroup
© BusinessWire
16.02.2025
BMY
LISTED
NYSE
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained consistent through five years with more than 5,000 patient-years of exposure in the trial...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). The safety profile of Opdualag observed in this analysis wa...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary endpoint in the marginal zone lymphoma (MZL) cohort. Results showed Breyanzi demonstrated a statistically significant and...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2024.
“We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key products and important pipeline advancements. We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizo...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), based on result...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory...
Themefolio
Profiler
Peergroup
© BusinessWire
25.01.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
News Preview
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Bristol Myers Squibb (NYSE: BMY) today announced results of an analysis from the...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
BMY
LISTED
NYSE
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025.
The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PT/10:30 a.m. ET.
The event will be webcast simultaneously at http://investor.bms.com, with materi...
Themefolio
Profiler
Peergroup
© BusinessWire
27.12.2024
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20), in most previously approved adult, solid tumor Opd...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu-t...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
“Colorectal cancer is th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2024 on Thursday, February 6, 2025. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.
Investors and the general public are invited to listen to a li...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend Increase
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on February 3, 2025, to stockholders of record at the close of business on January 3, 2025.
This quarterly dividend represe...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
News Preview
Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including autoimmune diseases. These results, covering a...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2024 Global Healthcare Conference.
Christopher Boerner, Ph.D., board chair and chief executive officer, will take part in a fireside chat on December 3, 2024. He will answer questions about the company beginning at 8:00 a.m. ET.
Investors and the gener...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research programs at the 66th American Society of Hematology (ASH) Annual Meeting and Expositio...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dM...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and fo...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois. New analyses include updated results from the nearly two-year post-launch evaluation of the CAMZYOS® (mavacamten)...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.
Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks of treatment. Data were presented at the 2024 Psych Congress, taking...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024.
“We made important strides in the third quarter with the landmark U.S. approval of Cobenfy in schizophrenia, continued sales momentum, strong cash flow generation and key pipeline achievements,” said Christopher Boerner, Ph.D., board chair and chief executive of...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 – November 2 in Boston, Massachusetts.
“Bui...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) for the treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rear...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
News Preview
Bristol Myers Squibb (NYSE:BMY) today announced positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu (deucravacitinib) for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in t...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
BMY
LISTED
NYSE
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating s...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
BMY
LISTED
NYSE
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with Zeposia (ozanimod) for relapsing forms of multiple sclerosis. These findings showed that patients receiving continuous Zeposia t...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced 10-year follow-up data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, which showed continued durable improvement in survival with first-line Opdivo® (nivolumab) plus Yervoy® (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untrea...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.
Investors and the general public are invited to listen to a live...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024.
In addition, the Board of Directors...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of nearly 60 abstracts of company-sponsored studies, investigator-sponsored studies, and collaborations from across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2024 to be held from September 13-17 in Barcelona, Spain.
“Our data a...
Themefolio
Profiler
Peergroup
© BusinessWire
01.09.2024
BMY
LISTED
NYSE
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating CAMZYOS® (mavacamten) in adult patients with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The long-term follow-up effica...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024.
Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Gl...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
BMY
LISTED
NYSE
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 30 – September 2, 2024, in London, England. Data to be presented at the meeting includes long-term extension data evaluating the efficacy and safety profi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
BMY
LISTED
NYSE
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC), based on results from the Phase...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
BMY
LISTED
NYSE
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its Type II variation application to expand the indication for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, to include the treatment of adult patients with relapsed or refractory...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
